{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-24-000137","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2024-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.019480+00:00","generated_at":"2026-05-31T13:31:10.914766+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Xeris Biopharma promotes Kevin McCulloch to President and COO","bullets":["Kevin McCulloch, former Chief Commercial Officer, was promoted to President and COO effective August 1, 2024.","McCulloch will receive an annual base salary of $520,000 and a target annual incentive of 50% of base salary.","He was granted 150,000 restricted stock units vesting over 3 years and 200,000 stock appreciation rights vesting at 2 years.","Severance includes 1.25x salary plus target incentive if terminated without cause, or 1.5x if within 12 months after a change in control.","McCulloch reports to CEO John Shannon and joined Xeris in 2018 as SVP of Global Operations and Business Development."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-24-000137","json":"https://secwatch.observer/filing/0001867096-24-000137.json","markdown":"https://secwatch.observer/filing/0001867096-24-000137.md","text":"https://secwatch.observer/filing/0001867096-24-000137.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709624000137/0001867096-24-000137-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709624000137/xers-20240801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:31:10.914766+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5df4b0d144","claim":"Kevin McCulloch changed role as President and Chief Operating Officer at Xeris Biopharma Holdings, Inc..","evidence_excerpt":"The Board of Directors of Xeris Biopharma Holdings, Inc. (the “Company”) promoted Kevin McCulloch to be President and Chief Operating Officer of the Company, effective as of August 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000186709624000137/0001867096-24-000137-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"President and Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}